The Therapeutic Landscape in Chronic Cough

Research output: Contribution to journalReview articlepeer-review

Abstract

In recent years, there has been a substantial increase in the development of antitussive therapies and the first new therapy, gefapixant has been licenced in Europe. This review describes current unlicenced treatments for chronic cough and details treatments currently in development for refractory chronic cough and cough in idiopathic pulmonary fibrosis, as well as compounds previously explored.

Original languageEnglish
Pages (from-to)5-16
Number of pages12
JournalLung
Volume202
Issue number1
Early online date21 Dec 2023
DOIs
Publication statusPublished - 1 Feb 2024

Keywords

  • Antitussives
  • Idiopathic pulmonary fibrosis
  • P2X3 antagonists
  • Refractory chronic cough

Fingerprint

Dive into the research topics of 'The Therapeutic Landscape in Chronic Cough'. Together they form a unique fingerprint.

Cite this